tbuckley/cabot-search huggingface dataset:
Linkage exclusion between the autosomal dominant polycystic kidney disease locus and chromosome 16 markers in a new family.
Authors: J E Brissenden, J M Roscoe, N E Simpson, M Silverman
Journal: Journal of the American Society of Nephrology (1991)

A family segregating for autosomal dominant polycystic kidney disease (ADPKD) is reported. The clinical picture was typical for ADPKD in some family members, although others showed mild involvement. DNA from family members was probed with seven chromosome 16 single-copy DNA sequences that mapped to the telomere of the short arm of the chromosome. The most likely order of six of the probes from the telomere is palpha3'HVR.64 at the designated locus D16S85, CRI-0327 at D16S63, CRI-090 at D16S45, CRI-0129 at D16S56, CRI-0133 at D16S58, and CRI-0136 at D16S60, with the PKD1 locus for ADPKD between D16S85 and D16S63. The seventh probe 24-1 at D16S80 had not been ordered in relation to the other sequences, but PKD1 had been mapped between it and D16S85. The three probes that were informative in our family, palpha3'HVR.64, CRI-090, and CRI-0136 had been linked to the disease locus at recombination frequencies of 4% and approximately 6 and 12%, respectively. Linkage was excluded between the ADPKD locus in our family and palpha3'HVR.64 at a recombination value of up to 6%. Linkage was also excluded between CRI-090 and the disease locus at a recombination value of up to 5%. The data for linkage between CRI-0136 and the ADPKD locus in our family were inconclusive. Multipoint analysis excluded the possibility that the disease in this family lies between the flanking genetic markers that have previously been used to define the genetic interval in which the most common form of polycystic kidney disease, PKD1, lies. We have not made a positive assignment of the ADPKD mutation in this family.(ABSTRACT TRUNCATED AT 250 WORDS)
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
Authors: D Mavroudis, A Alexopoulos, N Ziras, N Malamos, C Kouroussis, S Kakolyris, S Agelaki, K Kalbakis, N Tsavaris, A Potamianou, G Rigatos, V Georgoulias
Journal: Annals of Oncology (2000)
WITHDRAWN: Effects of cyclodextrins on function of various transporters in vinblastine-resistant Caco-2 cell monolayers
Authors: Hidetoshi Arima, Tadatoshi Morikawa, Yuko Yamasaki, Kiyokazu Yunomae, Keiichi Motoyama, Taishi Higashi
Journal: Asian Journal of Pharmaceutical Sciences (2015)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Clinical and cost effectiveness of booklet based vestibular rehabilitation for chronic dizziness in primary care: single blind, parallel group, pragmatic, randomised controlled trial
Journal: BMJ (2012)

Clinical and cost effectiveness of booklet based vestibular rehabilitation for chronic dizziness in primary care: single blind, parallel group, pragmatic, randomised controlled trialThere are a few errors in table 3 of this Research paper (BMJ 2012;344:e2237, doi:10
Bilan des infections professionnelles par le VIH : les données de la littérature jusqu'en décembre 1997
Authors: B G Evans, D Abiteboul
Journal: Eurosurveillance (1999)

Depuis le premier cas documente de seroconversion apres exposition professionnelle au VIH, en 1984 (1), de nombreux pays industrialises ont mis en place des systemes nationaux ou regionaux de surveillance des infections professionnelles par le VIH. Une serie de bilans des cas mondiaux, bases sur les articles publies, ont ete realises en 1992 (2), 1993 (3), 1995 (4), et plus recemment, en 1997 (5). L’incidence reelle de l’infection professionnelle par le VIH n’est pas connue et est vraisemblablement plus importante que le nombre total de cas rapportes, y compris dans les pays industrialises d’ou sont originaires les publications. L’incidence mondiale est sans doute beaucoup plus elevee etant donne le faible nombre d’infections professionnelles rapporte dans les regions de forte prevalence ou les systemes de surveillance sont moins developpes.
HIF-1 and paradoxical phenomena in cardioprotection: EXPERT'S PERSPECTIVE
Authors: G. Heusch
Journal: Cardiovascular Research (2012)

This editorial refers to an article by Z. Cai et al .,[12][1] published in Cardiovascular Research in 2008. It is accompanied by a retrospective editorial by one of the authors of that original article, G.L. Semenza, pp. 216–219, this issue, as part of this Spotlight on Landmark Papers in Cardiovascular Research . 

Ischaemic preconditioning, i.e. one or several brief cycles of myocardial ischaemia/reperfusion preceding a more sustained period of myocardial ischaemia with subsequent reperfusion, does not increase the resulting size of myocardial infarction but paradoxically decreases it.1 Over the past 25 years, ischaemic preconditioning has become the key paradigm of endogenous cardioprotection, and numerous studies have addressed its underlying signal transduction.2,3 In principle, ischaemic preconditioning's protection is also operative in humans, although—apart from the controlled situation of surgical coronary revascularization—it is difficult to apply therapeutically due to the unpredictable nature of acute myocardial infarction.4

The role of reactive oxygen species (ROS) in the signalling of cardioprotection …

 [1]: #ref-12
Immune history profoundly affects broadly protective B cell responses to influenza
Authors: Sarah F. Andrews, Yunping Huang, Kaval Kaur, Lyubov I. Popova, Irvin Y. Ho, Noel T. Pauli, Carole J. Henry Dunand, William M. Taylor, Samuel Lim, Min Huang, Xinyan Qu, Jane-Hwei Lee, Marlene Salgado-Ferrer, Florian Krammer, Peter Palese, Jens Wrammert, Rafi Ahmed, Patrick C. Wilson
Journal: Science Translational Medicine (2015)

Generating a broadly protective influenza vaccine is critical to global health. Understanding how immune memory influences influenza immunity is central to this goal. We undertook an in-depth study of the B cell response to the pandemic 2009 H1N1 vaccine over consecutive years. Analysis of monoclonal antibodies generated from vaccine-induced plasmablasts demonstrated that individuals with low preexisting serological titers to the vaccinating strain generated a broadly reactive, hemagglutinin (HA) stalk-biased response. Higher preexisting serum antibody levels correlated with a strain-specific HA head-dominated response. We demonstrate that this HA head immunodominance encompasses poor accessibility of the HA stalk epitopes. Further, we show polyreactivity of HA stalk-reactive antibodies that could cause counterselection of these cells. Thus, preexisting memory B cells against HA head epitopes predominate, inhibiting a broadly protective response against the HA stalk upon revaccination with similar strains. Consideration of influenza exposure history is critical for new vaccine strategies designed to elicit broadly neutralizing antibodies.
Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker
Authors: Wenjun Ju, Viji Nair, Shahaan Smith, Li Zhu, Kerby Shedden, Peter X. K. Song, Laura H. Mariani, Felix H. Eichinger, Celine C. Berthier, Ann Randolph, Jennifer Yi-Chun Lai, Yan Zhou, Jennifer J. Hawkins, Markus Bitzer, Matthew G. Sampson, Martina Thier, Corinne Solier, Gonzalo C. Duran-Pacheco, Guillemette Duchateau-Nguyen, Laurent Essioux, Brigitte Schott, Ivan Formentini, Maria C. Magnone, Maria Bobadilla, Clemens D. Cohen, Serena M. Bagnasco, Laura Barisoni, Jicheng Lv, Hong Zhang, Hai-Yan Wang, Frank C. Brosius, Crystal A. Gadegbeku, Matthias Kretzler
Journal: Science Translational Medicine (2015)

Renal and urinary EGF can serve as biomarkers for prediction of outcomes in chronic kidney disease.
Using an outbreak to study the sensitivity of the surveillance of enterohaemorrhagic Escherichia coli and other enteropathic Escherichia coli in Bavaria, Germany, January to October 2011
Authors: H Englund, W Hautmann
Journal: Eurosurveillance (2012)

Following an outbreak of enterohaemorrhagic Escherichia coli (EHEC) in Germany 2011, we observed increases in EHEC and non-EHEC E. coli cases in Bavaria. We compared the demographic, clinical and laboratory features of the cases reported during the outbreak period, but not related to the outbreak, to the cases reported before and after. The number of EHEC and non-EHEC E. coli cases notified per week during the outbreak was fivefold and twofold higher respectively, compared to previous years. EHEC cases notified during the outbreak were more often reported with bloody diarrhoea, and less often with unspecified diarrhoea, compared to the other periods. They were more often hospitalised during the outbreak and the following period compared to the period before. Their median age (26.5 years, range: 0–90) was higher compared to before (14.5 years, range: 0–94) and after (5 years, range: 0–81). The median age of non-EHEC E. coli cases notified during the outbreak period (18 years, range 0–88) was also higher than before and after (2 years, p<0.001). The surveillance system likely underestimates the incidence of both EHEC and non-EHEC E. coli cases, especially among adults, and overestimates the proportion of severe EHEC cases. Testing all stool samples from patients with diarrhoea for enteropathic E. coli should be considered.
A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome
Authors: Michael J. Schell, Mingli Yang, Edoardo Missiaglia, Mauro Delorenzi, Charlotte Soneson, Binglin Yue, Michael V. Nebozhyn, Andrey Loboda, Gregory Bloom, Timothy J. Yeatman
Journal: Clinical Cancer Research (2015)

We previously found that an epithelial-to-mesenchymal transition (EMT)-based gene expression signature was highly correlated with the first principal component (PC1) of 326 colorectal cancer tumors and was prognostic. This study was designed to improve these signatures for better prediction of metastasis and outcome.A total of 468 colorectal cancer tumors including all stages (I-IV) and metastatic lesions were used to develop a new prognostic score (ΔPC1.EMT) by subtracting the EMT signature score from its correlated PC1 signature score. The score was validated on six other independent datasets with a total of 3,697 tumors.ΔPC1.EMT was found to be far more predictive of metastasis and outcome than its parent scores. It performed well in stages I to III, among microsatellite instability subtypes, and across multiple mutation-based subclasses, demonstrating a refined capacity to predict distant metastatic potential even in tumors with a "good" prognosis. For example, in the PETACC-3 clinical trial dataset, it predicted worse overall survival in an adjusted multivariable model for stage III patients (HR standardized by interquartile range [IQR] = 1.50; 95% confidence interval, 1.25-1.81; P = 0.000016, N = 644). The improved performance of ΔPC1.EMT was related to its propensity to identify epithelial-like subpopulations as well as mesenchymal-like subpopulations. Biologically, the signature was correlated positively with RAS signaling but negatively with mitochondrial metabolism. ΔPC1.EMT was a "best of assessed" prognostic score when compared with 10 other known prognostic signatures.The study developed a prognostic signature score with a propensity to detect non-EMT features, including epithelial cancer stem cell-related properties, thereby improving its potential to predict metastasis and poorer outcome in stage I-III patients.
Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin
Authors: Eli I Lev, David Hasdai, Erez Scapa, Ana Tobar, Abid Assali, Judith Lahav, Alexander Battler, Juan J Badimon, Ran Kornowski
Journal: Journal of the American College of Cardiology (2004)
Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates Multiple Genetic Mechanisms
Authors: Alissa M. D’Gama, Sirisha Pochareddy, Mingfeng Li, Saumya S. Jamuar, Rachel E. Reiff, Anh-Thu N. Lam, Nenad Sestan, Christopher A. Walsh
Journal: Neuron (2015)
LP27 : ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase
Authors: E. Gane, C. Schwabe, C. Stedman, F. Weilert, K. Stuart, W. Cheng, J. Yang, H. Robison, J. Hui, J. Lahey, R. Sorensen, D. Apelian, R. Hindes
Journal: Journal of Hepatology (2015)
Exploratory Analysis of Circulating Free Dna to Identify Biomarkers Predictive of Outcome in Galaxy-1, a Large Randomized Phase Iib Study of Ganetespib in Combination with Docetaxel Versus Docetaxel Alone in Advanced Nsclc (Nct01348126)
Authors: D. Fennell, J. Shaw, I. El-Hariry, V. Reichert, V. Vukovic, L.M. Martins
Journal: Annals of Oncology (2014)
The Biological Relevance of Arachidonic Acid Metabolism in Human Brain Tumors
Authors: Paolo Gaetani, Chiara Chiabrando, Marco Danova, Fulvio Marzatico, Vittorio Silvani, Giorgio Butti, Riccardo Rodriguez Y. Baena
Journal: Neuro-Oncology (1991)

The biological relevance of arachidonic acid metabolism in 30 human intracranial meningiomas and 30 gliomas was investigated with particular regards to the metabolic patterns, the relationship between arachidonic acid metabolism and cell kinetic aspects, steroid hormone receptors expression, peri-lesional brain edema.
Flagship £800m contract collapses after just eight months
Authors: Gareth Iacobucci
Journal: BMJ (2015)

A landmark £800m (€1.3bn; $1.4bn) contract to provide older people’s healthcare and adult community services in Cambridgeshire has collapsed just months into operation of the services, after it was deemed “no longer financially sustainable.”

The provider, UnitingCare Partnership (a limited liability partnership formed by Cambridgeshire and Peterborough NHS Foundation Trust and Cambridge University Hospitals NHS Foundation Trust) had been running the service only since April 2015.1 But the contract, one of the largest outsourcing deals ever in the NHS, has been handed back to Cambridgeshire and Peterborough Clinical Commissioning Group after both parties agreed to dissolve the five year deal.

The integrated …
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
Authors: Kevin J. Hamblett, Allison P. Jacob, Jesse L. Gurgel, Mark E. Tometsko, Brooke M. Rock, Sonal K. Patel, Robert R. Milburn, Sophia Siu, Seamus P. Ragan, Dan A. Rock, Christopher J. Borths, Jason W. O'Neill, Wesley S. Chang, Margaret F. Weidner, Matthew M. Bio, Kim C. Quon, William C. Fanslow
Journal: Cancer Research (2015)

Antibody-drug conjugates (ADC) target cytotoxic drugs to antigen-positive cells for treating cancer. After internalization, ADCs with noncleavable linkers are catabolized to amino acid-linker-warheads within the lysosome, which then enter the cytoplasm by an unknown mechanism. We hypothesized that a lysosomal transporter was responsible for delivering noncleavable ADC catabolites into the cytoplasm. To identify candidate transporters, we performed a phenotypic shRNA screen with an anti-CD70 maytansine-based ADC. This screen revealed the lysosomal membrane protein SLC46A3, the genetic attenuation of which inhibited the potency of multiple noncleavable antibody-maytansine ADCs, including ado-trastuzumab emtansine. In contrast, the potencies of noncleavable ADCs carrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation. Structure-activity experiments suggested that maytansine is a substrate for SLC46A3. Notably, SLC46A3 silencing led to relative increases in catabolite concentrations in the lysosome. Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens.
Right Ventricular Myxoma Simulating Pulmonic Stenosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Specificity of risk factors for depression
Authors: A Roy
Journal: American Journal of Psychiatry (1981)

The author compared 94 depressed patients with 94 nondepressed patients who had a personality disorder in a matched control study. A family history of depression, parental loss before 17 years, and unemployment were found to be risk factors associated with depression in the women. In the men, however, parental loss was the only factor associated with depression.
Health and Climate Change 1 Public health benefits of strategies to reduce greenhouse-gas emissions: household energy
Authors: Paul Wilkinson, Kirk R Smith, Michael Davies, Heather Adair, Ben G Armstrong, Mark Barrett, Nigel Bruce, Andy Haines, Ian Hamilton, Tadj Oreszczyn, Ian Ridley, Cathryn Tonne, Zaid Chalabi
Journal: The Lancet (2009)
Distribution of Ribonucleoprotein and Protein-Only RNase P in Eukarya
Authors: Marcus Lechner, Walter Rossmanith, Roland K. Hartmann, Clemens Thölken, Bernard Gutmann, Philippe Giegé, Anthony Gobert
Journal: Molecular Biology and Evolution (2015)

RNase P is the endonuclease that removes 5′ leader sequences from tRNA precursors. In Eukarya, separate RNase P activities exist in the nucleus and mitochondria/plastids. Although all RNase P enzymes catalyze the same reaction, the different architectures found in Eukarya range from ribonucleoprotein (RNP) enzymes with a catalytic RNA and up to 10 protein subunits to single-subunit protein-only RNase P (PRORP) enzymes. Here, analysis of the phylogenetic distribution of RNP and PRORP enzymes in Eukarya revealed 1) a wealth of novel P RNAs in previously unexplored phylogenetic branches and 2) that PRORP enzymes are more widespread than previously appreciated, found in four of the five eukaryal supergroups, in the nuclei and/or organelles. Intriguingly, the occurrence of RNP RNase P and PRORP seems mutually exclusive in genetic compartments of modern Eukarya. Our comparative analysis provides a global picture of the evolution and diversification of RNase P throughout Eukarya.
AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease
Authors: Tomomi Kiyota, Gang Zhang, Christine M Morrison, Megan E Bosch, Robert A Weir, Yaman Lu, Weiguo Dong, Howard E Gendelman
Journal: Molecular Therapy (2015)

Modulation of the amyloid-β (Aβ) trafficking pathway heralds a new therapeutic frontier for Alzheimer's disease (AD). As CD74 binds to the amyloid-β precursor protein (APP) and can suppresses Aβ processing, we investigated whether recombinant adeno-associated virus (AAV) delivery of CD74 could reduce Aβ production and affect disease outcomes. This idea was tested in a mouse AD model. Cotransduction of AAV-tetracycline-controlled transactivator (tTA) and AAV-tet-response element (TRE)-CD74 resulted in CD74 expression, reduced Aβ production in mouse neurons containing the human APP with familial AD-linked mutations. Stereotaxic injection of AAV-TRE-GFP or CD74 into the hippocampi of an AD mouse, defined as a TgCRND8 × calmodulin-dependent protein kinase II derived promoter-tTA double-transgenic, reduced Aβ loads and pyramidal neuronal Aβ accumulation in the hippocampus. Immunofluorescent studies showed that APP colocalization with Lamp1 was increased in CD74-expressing neurons. Moreover, Morris water maze tasks demonstrated that mice treated with AAV-TRE-CD74 showed improved learning and memory compared to AAV-TRE-GFP control animals. These results support the idea that CD74-induced alteration of Aβ processing could improve AD-associated memory deficits as shown in mouse models of human disease. Modulation of the amyloid-β (Aβ) trafficking pathway heralds a new therapeutic frontier for Alzheimer's disease (AD). As CD74 binds to the amyloid-β precursor protein (APP) and can suppresses Aβ processing, we investigated whether recombinant adeno-associated virus (AAV) delivery of CD74 could reduce Aβ production and affect disease outcomes. This idea was tested in a mouse AD model. Cotransduction of AAV-tetracycline-controlled transactivator (tTA) and AAV-tet-response element (TRE)-CD74 resulted in CD74 expression, reduced Aβ production in mouse neurons containing the human APP with familial AD-linked mutations. Stereotaxic injection of AAV-TRE-GFP or CD74 into the hippocampi of an AD mouse, defined as a TgCRND8 × calmodulin-dependent protein kinase II derived promoter-tTA double-transgenic, reduced Aβ loads and pyramidal neuronal Aβ accumulation in the hippocampus. Immunofluorescent studies showed that APP colocalization with Lamp1 was increased in CD74-expressing neurons. Moreover, Morris water maze tasks demonstrated that mice treated with AAV-TRE-CD74 showed improved learning and memory compared to AAV-TRE-GFP control animals. These results support the idea that CD74-induced alteration of Aβ processing could improve AD-associated memory deficits as shown in mouse models of human disease.
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
Authors: Naiyer Rizvi, Jamie Chaft, Ani Balmanoukian, Sarah B Goldberg, Rachel E Sanborn, Keith E Steele, Marlon C Rebelatto, Yu Gu, Joyson J Karakunnel, Scott Antonia
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts As single agents, durvalumab (MEDI4736), a human IgG1 anti-PD-L1 antibody, and tremelimumab, a human IgG2 anti-CTLA-4 antibody, have shown acceptable safety profiles and antitumor activity. Similar to other anti-PD-L1/anti-PD-1 monotherapies, durvalumab has shown greater objective
Photodynamic Therapy for Pancreatic and Biliary Tract Cancer: The United Kingdom Experience
Authors: Stephen Pereira
Journal: Journal of the National Comprehensive Cancer Network (2012)

Pancreaticobiliary cancer remains a challenging cancer to treat, with a small group of patients having resectable disease and few long-term survivors. Stenting remains the treatment of choice for biliary obstruction, but optimal stenting is difficult. Resection and chemoradiotherapy are indicated for localized pancreatic cancer, and gemcitabine-based chemotherapy may be considered the standard of care for advanced/metastatic pancreatic disease. In the search for better therapeutic alternatives, the role of photodynamic therapy (PDT) for both pancreatic and biliary tract cancers has been evaluated. Although conflicting and often poor-quality data have emerged on the use of PDT for unresectable bile duct cancers and encouraging early-stage studies with PDT are under way for unresectable, locally advanced pancreatic cancer, definitive answers as to its efficacy can only be found in randomized controlled trials.